AQUALUNG
Aqualung , the leading global designer and manufacturer of dive and water sports gear, today announced the launch of its all new XSCAPE collection. Featuring a 100 percent neoprene-free wetsuit and a rash guard made from sustainable materials, the XSCAPE line is designed for a variety of water activities and reflects Aqualung’s commitment to innovation, ocean discovery and sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210427005227/en/
Made with Yulex® eco-friendly natural rubber and ultra-stretch fabric, the 4/3mm XSCAPE wetsuit provides enhanced comfort for diving in warm waters or above surface activities in colder temperatures, and can be used for scuba diving, snorkeling, freediving, paddling or a variety of other water sports. The flexible and lightweight XSCAPE wetsuit, available in a red and olive design for men and a tropical-inspired print for women, connects consumers to nature and the natural materials the collection is made from. The suit also features Powertex knee pads, recycled, quick-drying fleece around the torso area to provide additional warmth and comfort, and a reusable mesh bag for storage after use or collecting trash from the beach or water.
“The XSCAPE collection continues Aqualung's legacy in innovation, and their tireless work to create the most forward thinking and eco-conscious dive company in the world,” said Aqualung global ocean ambassador Philippe Cousteau Jr., the grandson of one of Aqualung’s original founders, Captain Jacques-Yves Cousteau. “We all have the power to change the world with the choices we make, and the XSCAPE sets the new standard for wetsuits and rash guards that are stylish, functional and sustainable.”
The new collection’s long-sleeve rash guard for men and women, and matching women’s leggings, offer maximum comfort and breathability and can be used above or below the surface. All rash guards and leggings feature UV protection and are made with polyester fabric sourced from recycled plastic bottles. The entire XSCAPE line comes in plastic-free packaging with hangtags made from recycled cardboard.
“Our aim was to design the ultimate eco-friendly wetsuit that could be used for all kinds of water sports,” said Laurent Boury, Senior Vice President of Brands at Aqualung Group. “Aqualung is committed to using environmentally-friendly materials and processes whenever possible to help reduce our carbon footprint, and we made design choices to ensure the XSCAPE collection was as sustainable as possible.”
“The collection name, XSCAPE, is meant to evoke the feeling of freedom and the quest for wonder that surround exploration, travel and Aqualung’s storied history, including the first ‘aqua-lung’ created by Captain Jacques-Yves Cousteau and engineer Emile Gagnan that made underwater exploration possible,” added Boury.
The XSCAPE collection is available at authorized Aqualung retailers. Inventory may vary by region. To learn more, please visit www.aqualung.com .
About Aqualung Brand
Aqualung, part of the Aqualung Group, is the leading global designer and manufacturer of dive and water sports gear. Now available in more than 100 countries around the world, Aqualung pioneered the creation of modern diving equipment when Captain Jacques-Yves Cousteau teamed with engineer Emile Gagnan in 1943 to develop the first “aqua-lung,” making underwater exploration possible. Aqualung is committed to providing sustainable, innovative, reliable, and easy-to-use products that allow adventure seekers to enjoy responsible water exploration and continues to set the industry standard for water sports equipment in technology, comfort, safety and design. For more information, visit www.aqualung.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210427005227/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom